ever4010001
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 30, 2020 (NCT04699643)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 4INHIBITOR
FGFR4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04699643 | Phase 1/Phase 2 (Phase 2) | Jul 30, 2020 | Everest Medicines, Medidata Solutions, People's Liberation Army of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Everest Medicines | For profit | 1 | 1 | 1 | 2020 |
| Medidata Solutions | For profit | 1 | 0 | 1 | 2020 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1